U.S. stocks ended little changed as investors eyed the jobs report and were on edge ahead of Greece's Sunday referendum.
Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.
Ten so-called breakthrough drugs for cancers and chronic conditions will cost taxpayers big bucks.
Negative revenue growth will continue to dog investors in Q2 and Q3, analyst Mike Thompson says. Here's what to do about it.
Some of the names on the move ahead of the open.
Take a look at some of Tuesday's after-hours buzz: American Express, Vertex & more
The next takeout target in biotech? Here are three eligible candidates
Brian Sullivan and Dom Chu will list the top 40 cheapest stock picks from Goldman Sachs.
President Obama will dedicate $215 million in his budget request to a program that will target the underlying cause of disease.
The heads of research at several large drugmakers have received mysterious invitations to the White House for a meeting Friday morning.
The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.
Some of Wednesday's midday movers:
U.S. Treasury yields continued to rise on Tuesday amid data and expectations of Fed action.
Health care has been on a tear in 2014, and there is still room for upside. Wall Street analysts are focusing on the following four trends.
Some of Monday's midday movers:
Stocks cut losses to close mixed on Thursday as geopolitical tensions lingered ahead of consumer data.
U.S. stocks closed higher for the third time in four days as a rally in tech, airlines and biotech firms helped lead gains.
Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.
The liver disease NASH is becoming more widespread, and the market for treatments may rival those for hepatitis C.
Uncertain how to put money to work in a market that continues to flirt with all-time highs? Jim Cramer has a few ideas. Ten of them.